Sino Biopharmaceutical - B (06938): Hong Kong public offering receives 101.06 times oversubscription.

22:52 08/01/2026

Ribo Bio-B (06938) announced the results of the placement, with a total of 31.6104 million H shares sold globally. The public offering accounted for 8.7%, while the international offering accounted for 91.3%. The offering price per share was HK$57.97, with a total net proceeds of approximately HK$1.702 billion from the global offering. Each lot consists of 200 shares, and it is expected that H shares will begin trading on the Hong Kong Stock Exchange on January 9, 2026, at 9:00 a.m.

RayBiotech-B (06938) announced the results of its distribution, with a total of 31.6104 million H shares being sold globally. The public offering accounted for 8.7%, while the international offering accounted for 91.3%. The price per share was 57.97 Hong Kong dollars, with a total net proceeds of approximately 1.702 billion Hong Kong dollars from the global offering. Trading of the H shares is expected to commence on the Stock Exchange on January 9, 2026, at 9:00 AM. The public offering in Hong Kong was oversubscribed by 101.06 times, while the international offering was oversubscribed by 16.7 times.

OOIL (00316) reported a 17.2% decrease in route revenue in the fourth quarter compared to the same period last year. Total cargo volume increased by 0.8% and carrying capacity increased by 4.5%.

Medicalsystem Biotechnology (300439.SZ) obtained two medical device registration certificates.

NEO-NEON (01868) spent HK$17,000 on January 9th to repurchase 44,000 shares.

OOIL (00316) reported a 17.2% decrease in route revenue in the fourth quarter compared to the same period last year. Total cargo volume increased by 0.8% and carrying capacity increased by 4.5%.

Medicalsystem Biotechnology (300439.SZ) obtained two medical device registration certificates.

NEO-NEON (01868) spent HK$17,000 on January 9th to repurchase 44,000 shares.